NCT06650384View on ClinicalTrials.gov

Efficacy and Safety of N-Acetylcysteine Versus Alpha-Lipoic Acid in Colistin-Induced Nephrotoxicity

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

February 1, 2026

Conditions
Nephrotoxicity
Interventions
DRUG

Addition of sachets of N-acetyl cysteine 1200 mg twice/day to the maintenance dose of colistin

Group2 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose of 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral sachets of N-acetyl cysteine 1200 mg twice /day

DRUG

Addition of Alpha-lipoic acid 600mg twice daily to the maintenance dose of colistin

Group3 (n=60): (IV) colistin 300mg CBA loading dose then maintenance dose 150-180 mg CBA twice daily based on Crcl calculated using Cockcroft -Gault equation in addition to enteral Alpha-lipoic acid 600mg twice/day

Trial Locations (1)

Unknown

RECRUITING

Critical Care Medicine Department,Cairo University Hospitals, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER